FDA Essure Actions Draw Lawmaker Ire, Demand For Product Withdrawal

While FDA has gone beyond an advisory committee recommendation to require a registry to monitor Bayer's Essure permanent contraception device, lawmakers say the agency's call for a new postmarket study and black box labeling requirements spelled out in a draft guidance are insufficient to address serious concerns with safety.